By Billy Candra 
A paradigm-shifting study from the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center (MSK) has resolved a long-standing paradox in colorectal cancer research, identifying distinct subtypes of regulatory T (Treg) cells with opposing roles in tumor progression. While large numbers of Treg cells are typically associated with worse outcomes in most solid tumors due to their function as immune system "brakes," colorectal cancer has stood out as a perplexing exception, where higher Treg counts often correlate with improved patient survival. The new findings, published in the prestigious scientific journal Immunity, provide a clear mechanistic explanation for this anomaly and lay the groundwork for more targeted and effective immunotherapies, particularly for the most common forms of colorectal cancer that have historically shown limited responses to existing treatments.
The Enigma of Treg Cells in Cancer
Regulatory T cells are a specialized subset of T lymphocytes, crucial components of the adaptive immune system. Their primary function is to maintain immune tolerance, preventing the immune system from launching unprovoked attacks on the body’s own tissues, beneficial microbes, and harmless environmental substances. This essential role involves actively suppressing other immune cells, ensuring a balanced and controlled immune response. However, in the context of cancer, this suppressive capability often becomes a double-edged sword. Tumors frequently co-opt Treg cells, recruiting them to the tumor microenvironment where they can dampen anti-tumor immune responses, effectively shielding cancer cells from destruction by effector T cells, such as cytotoxic CD8+ T cells. This immunosuppression is why, in many cancers like melanoma, lung cancer, and renal cell carcinoma, a high infiltration of Tregs within the tumor is a reliable prognostic indicator of aggressive disease and poorer patient survival.
For decades, colorectal cancer presented a puzzling deviation from this general rule. Clinical observations consistently showed that patients with colorectal tumors exhibiting a higher density of Treg cells often experienced longer survival times. This counterintuitive correlation challenged the prevailing understanding of Treg function in oncology and left researchers searching for an explanation that could reconcile colorectal cancer’s unique immune landscape with the broader picture of cancer immunology.
A Decades-Long Quest Culminates in Breakthrough
The recent study, led by co-senior authors Alexander Rudensky, PhD, Chair of the Immunology Program at MSK and a Howard Hughes Medical Institute Investigator, and computational biologist Christina Leslie, PhD, builds upon more than two decades of foundational research by Dr. Rudensky. His pioneering work has been instrumental in establishing the identity, development, and function of Treg cells, elucidating their critical role in immune tolerance and their influence on various diseases, including cancer. The current investigation was spearheaded by first authors Xiao Huang, PhD, a postdoctoral researcher in the Rudensky Lab; Dan Feng, MD, PhD, a former MSK Medical Oncology fellow now at the Icahn School of Medicine at Mount Sinai; and Sneha Mitra, PhD, a postdoctoral researcher in Dr. Leslie’s lab. Their collaborative effort combined cutting-edge immunology with advanced computational biology to unravel the complexities of the colorectal tumor microenvironment.
"Instead of the regulatory T cells promoting tumor growth, as they do in most cancers, in colorectal cancer we discovered there are actually two distinct subtypes of Treg cells that play opposing roles — one restrains tumor growth, while the other fuels it," explained Dr. Rudensky. "It’s these beneficial Treg cells that make the difference, and this underscores the need for selective approaches." This statement succinctly captures the essence of the discovery: the sheer number of Treg cells is less important than their specific phenotype and functional orientation.
Unmasking the Opposing Forces: IL-10 Positive vs. IL-10 Negative Tregs
The MSK team’s critical insight came from realizing that "Treg cell" is not a singular entity. Through meticulous experiments utilizing a sophisticated mouse model that accurately mimics the genetic alterations, behavior, and immune context of human colorectal tumors, they identified two primary subpopulations of tumor-associated Treg cells. The defining characteristic distinguishing these groups was their ability to produce the signaling molecule interleukin-10 (IL-10).
-
The Beneficial Subtype: IL-10-Positive Treg Cells: These cells were found to actively slow tumor growth. Their mechanism of action involves reducing the activity of another immune cell type, Th17 cells, which produce interleukin-17 (IL-17). IL-17 is known to act as a growth signal for various tumors, promoting proliferation and angiogenesis. By suppressing Th17 cells and thus IL-17 production, the IL-10-positive Tregs effectively deprive the tumor of a crucial growth stimulant. Importantly, these protective Treg cells were observed more frequently in the healthy tissue surrounding the tumor, suggesting a role in maintaining local immune homeostasis and potentially preventing tumor expansion. When researchers selectively removed these IL-10-positive Treg cells in experimental models, tumors exhibited accelerated growth, underscoring their anti-tumor efficacy.
-
The Harmful Subtype: IL-10-Negative Treg Cells: In stark contrast, the IL-10-negative Treg cells exerted a detrimental effect on tumor control. These cells primarily suppressed powerful anti-cancer immune defenders, most notably CD8+ T cells. CD8+ T cells, often dubbed "killer T cells," are critical for directly recognizing and eliminating cancer cells. By inhibiting their activity, the IL-10-negative Tregs create an immunosuppressive environment that allows the tumor to evade immune surveillance. This harmful subtype was predominantly located within the tumor mass itself, where its suppressive effects could be maximally leveraged by the cancer. Experimental elimination of these IL-10-negative Treg cells resulted in significant tumor shrinkage, confirming their pro-tumor role.
Validating the Discovery in Human Colorectal Cancer
To translate these preclinical findings to human disease, the research team rigorously validated their observations using tumor samples from patients with colorectal cancer. They successfully identified the same two distinct populations of IL-10-positive and IL-10-negative Treg cells within human tumors. Further strengthening the clinical relevance of their discovery, the team analyzed outcomes for over 100 colorectal cancer patients. The results were striking: patients with higher levels of the beneficial IL-10-positive Treg cells exhibited significantly longer overall survival, consistent with the initial clinical paradox. Conversely, patients whose tumors contained a greater proportion of the harmful IL-10-negative Treg cells experienced poorer outcomes.
"This research shows how important these positive cells are," stated Dr. Huang. "And it highlights the need to develop therapies that can selectively eliminate the harmful Tregs while preserving the helpful ones." This sentiment encapsulates the future direction of therapeutic development: moving beyond broad immunosuppression to precision targeting of specific immune cell subsets.
Focusing on the Most Prevalent Colorectal Cancer Type
Colorectal cancer stands as the second leading cause of cancer-related death when men and women are considered together, according to statistics from the American Cancer Society. This study focused specifically on the most common form of the disease, which accounts for approximately 80% to 85% of all colorectal cancers. These tumors are characterized by being microsatellite stable (MSS) with proficient mismatch repair (MMRp), meaning their DNA exhibits relative stability. Unfortunately, this predominant group of colorectal cancers has notoriously poor response rates to current checkpoint inhibitor immunotherapies, a class of drugs that have revolutionized treatment for other cancers by unleashing the immune system.
Earlier research, also at MSK, had demonstrated the remarkable efficacy of checkpoint inhibitors against the opposite tumor type: cancers with high microsatellite instability (MSI-H) and mismatch repair deficiency (MMRd). In these cases, immunotherapy alone can often lead to dramatic responses, allowing many patients to avoid the arduous regimens of surgery, chemotherapy, and radiation. The new understanding of Treg heterogeneity in MSS-MMRp colorectal cancer offers a crucial avenue to improve treatment outcomes for the vast majority of patients who currently lack effective immunotherapy options.
CCR8: A Promising New Therapeutic Target
The findings from MSK not only elucidated the functional heterogeneity of Tregs but also identified a crucial molecular marker for the harmful subtype. The researchers discovered that the IL-10-negative Treg cells, the ones that suppress CD8+ T cells and promote tumor growth, express high levels of a protein called CCR8. Critically, these CCR8-expressing, harmful Tregs were found predominantly within the tumor microenvironment.
This discovery is particularly significant because earlier work from Dr. Rudensky’s lab, spearheaded by breast cancer surgeon George Plitas, MD, had already identified CCR8 as a highly expressed marker on tumor-infiltrating Treg cells in breast cancer and numerous other human cancers. That seminal research had suggested the potential for using antibodies to selectively deplete these CCR8-positive, harmful Treg cells. The hypothesis was that such targeted depletion could unleash the immune system’s anti-tumor capabilities while leaving the beneficial, non-CCR8-expressing Treg cells intact, thereby minimizing systemic autoimmune side effects.
"This idea of using CCR8-depleting antibodies, which was pioneered at MSK, is the main target of global efforts to bring regulatory T cell-based immunotherapy to the clinic," Dr. Rudensky emphasized. This highlights the immediate translational impact of the research. Multiple clinical trials are now underway at MSK and other leading institutions worldwide, testing CCR8-targeting antibodies both as monotherapy and in combination with existing immunotherapies. The new study provides compelling evidence and strengthens the rationale for advancing this strategy specifically for colorectal cancer, and potentially for other challenging tumor types.
Broader Implications: Beyond Colorectal Cancer
The impact of this research extends beyond colorectal cancer. The MSK team investigated a large dataset of T cells derived from 16 different cancer types to determine if similar immune patterns of Treg heterogeneity existed elsewhere. They indeed found comparable divisions between IL-10-positive and IL-10-negative Treg cells in several cancers affecting "barrier tissues" – namely, the skin, and the lining of the mouth, throat, and stomach.
"What these tissues have in common is that immune cells play a critical role in constantly defending and repairing them as they’re exposed to microbes and environmental stresses," explained Dr. Mitra, who led the extensive data analysis. This observation suggests a conserved evolutionary mechanism where different Treg subsets might be tailored to maintain immune homeostasis in specific tissue environments that are constantly interacting with the external world. Consequently, therapies designed to remove the harmful IL-10-negative Treg cells in colorectal cancer might also prove effective against these other cancers arising in barrier tissues, opening up a broader therapeutic landscape.
Metastatic Disease: A Different Immune Landscape
While the findings offer immense hope for primary colorectal tumors, the researchers also delved into the immune environment of metastatic disease. When they studied colorectal cancer that had spread to the liver, they observed a distinct and concerning immune pattern. In these metastatic tumors, the harmful IL-10-negative Treg cells significantly outnumbered the helpful IL-10-positive cells. This shift in balance profoundly altered the immune landscape. Unlike primary tumors, where selective depletion of the harmful subtype was key, removing all Treg cells in the metastatic context actually caused these tumors to shrink.
This critical finding underscores the dynamic nature of the tumor microenvironment and highlights the necessity for treatment strategies that are not only tailored to the specific tissue involved but also to the stage of the disease. A "one-size-fits-all" approach to Treg modulation is unlikely to be effective across all contexts, and personalized medicine approaches will need to account for these nuances in metastatic settings.
The Path Forward for Immunotherapy
The MSK study represents a monumental leap forward in understanding the intricate immunology of colorectal cancer. By dissecting the functional heterogeneity of regulatory T cells, researchers have not only solved a long-standing paradox but also identified a precise therapeutic vulnerability. The ability to selectively target and deplete the harmful, CCR8-expressing IL-10-negative Treg cells, while preserving the beneficial IL-10-positive subset, offers a compelling strategy to enhance anti-tumor immunity in a significant proportion of colorectal cancer patients who currently lack effective immunotherapy options.
The ongoing clinical trials evaluating CCR8-targeting antibodies are now imbued with stronger scientific rationale, potentially ushering in a new era of precision immunotherapy. This research exemplifies the power of detailed immunological investigation to transform our understanding of cancer and pave the way for innovative, life-saving treatments for a wide range of challenging malignancies.
Authors, Funding, and Disclosures
Additional authors who contributed to this landmark study include Emma Andretta, Nima Hooshdaran, Aazam Ghelani, Eric Wang, Joe Frost, Victoria Lawless, Aparna Vancheswaran, Qingwen Jiang, Cheryl Mai, and Karuna Ganesh. The Integrated Genomics Operation and the Single Cell Research Initiative at MSK were instrumental in providing key technological support for the research.
The study received substantial funding from various prestigious organizations, including the National Cancer Institute (P30 CA008748, U54 CA274492, T32 CA009512), the National Institute of Allergy and Infectious Diseases (AI034206), the Ludwig Center for Cancer Immunotherapy at MSK, the Howard Hughes Medical Institute, the Cancer Research Institute, and a Marie-José Kravis Fellowship in Quantitative Biology.
Dr. Rudensky has disclosed various affiliations, serving on scientific advisory boards and holding equity in several biotechnology companies, including Sonoma Biotherapeutics, RAPT Therapeutics, Coherus Oncology, Santa Ana Bio, Odyssey Therapeutics, and Nilo Therapeutics. He is also a scientific advisory board member of Amgen, BioInvent, and Vedanta Biosciences, has consulted for AbbVie, and serves as an editor of the Journal of Experimental Medicine and an editorial advisor to Immunity. Furthermore, Dr. Rudensky and Dr. Plitas are recognized as inventors on patents and patent applications held by MSK, specifically related to CCR8-based therapeutic depletion of tumoral Treg cells and novel antibodies against CCR8, highlighting the direct commercial and clinical potential of their scientific breakthroughs.
